Abstract Details

Title Identifying Risk Factors for Falls in Parkinson's Disease Using Non-UPDRS Balance Tests

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 171

Objective

Background BACKGROUND: The postural stability component of the UPDRS is widely used to identify risk of falls in PD patients. But patients also show significant impairments in turning, one-leg stance, and tandem gait. The severity of these impairments may be helpful in predicting falls in PD patients.

Design/Methods DESIGN/METHODS: 205 patients reported balance difficulty using a validated, self-administered question, the Barrow Neurological Institute (BNI) balance question. All patients were evaluated using the motor portion of the revised UPDRS and non-UPDRS balance tests including tandem gait, turning 360-degree turn, and standing on one foot. The t-test was used for comparing continuous variables and a chi-square test was used for comparing categorical variables.

Results RESULTS: 153 patients reported balance difficulty without falls, and 52 reported balance difficulty with falls (fallers). Fallers were significantly older, had PD longer, and were more disabled on the UPDRS total motor score. Fallers were significantly less able to turn 360 degrees, less able to balance on one foot, and less able to tandem walk. The sensitivity and specificity for different indices are: Turning: Sensitivity 58.3% & specificity 68.9%; Standing on one foot: 83.3% & 50.0%; Tandem walking: 79.2% & 66.7%.

Conclusions CONCLUSIONS: Standing on one foot and tandem gait had a high sensitivity in predicting falls while turning and tandem gait had a high specificity of predicting falls. These non-UPDRS tests of balance and tandem gait are useful supplements to the UPDRS in predicting falls.

Authors/Disclosures
Sara S. Dhanani, MD (Banner Sun Health Research Institute) PRESENTER	Dr. Dhanani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie.
Abraham N. Lieberman, MD, FAAN	No disclosure on file
Rohit Dhall, MD, FAAN (University of Arkansas for Medical Sciences)	Dr. Dhall has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Best Doctors Inc. Dr. Dhall has stock in Verve Therapeutics Inc. Dr. Dhall has stock in Roche Holding Limited. Dr. Dhall has stock in Enliven Therapeutics Inc. The institution of Dr. Dhall has received research support from Amneal. The institution of Dr. Dhall has received research support from Neuroderm. The institution of Dr. Dhall has received research support from Cerevel Therapeutics. The institution of Dr. Dhall has received research support from Neurocrine. The institution of Dr. Dhall has received research support from Neuraly. The institution of Dr. Dhall has received research support from SPARC. The institution of Dr. Dhall has received research support from Pharma2B. The institution of Dr. Dhall has received research support from Alexion. The institution of Dr. Dhall has received research support from Parkinsons Foundation. The institution of Dr. Dhall has received research support from UCB Pharma. The institution of Dr. Dhall has received research support from Inhibikase Therapeutics. The institution of Dr. Dhall has received research support from Amylyx Pharma.
Ashish Pradhan, MD (Genentech)	Dr. Pradhan has received personal compensation for serving as an employee of Genentech. Dr. Pradhan has received stock or an ownership interest from Genetech.
	No disclosure on file

��ɫ��

��ɫ��